With 1.72 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.64 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.55 whereas the lowest price it dropped to was $0.47. The 52-week range on YCBD shows that it touched its highest point at $1.34 and its lowest point at $0.31 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at 2.01.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of YCBD was up-trending over the past week, with a rise of 33.87%, but this was up by 4.84% over a month. Three-month performance surged to 9.21% while six-month performance fell -13.99%. The stock lost -32.94% in the past year, while it has gained 32.80% so far this year.
Float and Shares Shorts:
At present, 5.54 million YCBD shares are outstanding with a float of 4.60 million shares on hand for trading. On 2024-11-29, short shares totaled 0.19 million, which was 432.0 higher than short shares on 1730332800. In addition to Mr. T. Ronan Kennedy as the firm’s Interim CEO, CFO & Principal Executive Officer, Dr. Sibyl Swift Ph.D. serves as its CSO, VP of Regulatory Affairs & Director.
Institutional Ownership:
Through their ownership of 0.03329 of YCBD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, YCBD reported revenue of $4556366.0 and operating income of -$316555.0. The EBITDA in the recently reported quarter was -$103352.0 and diluted EPS was $nan.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With YCBD analysts setting a high price target of 2.0 and a low target of 2.0, the average target price over the next 12 months is 2.0. Based on these targets, YCBD could surge 300.0% to reach the target high and rise by 300.0% to reach the target low. Reaching the average price target will result in a growth of 300.0% from current levels.
Analysts have provided yearly estimates in a range of -$2.63 being high and -$2.63 being low. For YCBD, this leads to a yearly average estimate of -$2.63. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
